Author

Christopher B. Bullock

Ragon Institute of MGH, MIT and HarvardORCID 0000-0002-8081-7867Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Christopher B. Bullock1 paper · Genentech

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Adam D. NitidoiD· 1 shared Alejandro Benjamin BalazsiD· 1 shared Allen Z. LiniD· 1 shared Amarendra PeguiD· 1 shared Benjamin MooniD· 1 shared Cailin E. Deal· 1 shared Christine L. BoutrosiD· 1 shared Cuiping LiuiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

Adam D. NitidoORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MicrobiologyImmunityPeer-reviewedFeb 25, 2026

HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV vectored immunotherapy in humanized mice

Nicolás M. S. Gálvez, Adam D. Nitido, Seo Bin Yoo…·Alejandro Benjamin Balazs

This paper uses humanized mice to study how HIV resistance to broadly neutralizing antibodies (bNAbs) affects the efficacy of AAV-delivered immunotherapy, finding that escape mutation fitness costs and resistance benefits determine therapeutic success.

3 citations

humanexperimental assay

𝕏 PostBluesky